NCT06880549 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06880549
Title	A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	ModernaTX, Inc.
Indications	colon adenocarcinoma urinary bladder cancer endometrial carcinoma melanoma lung non-small cell carcinoma esophageal carcinoma ovarian carcinoma head and neck squamous cell carcinoma cervix carcinoma stomach carcinoma hepatocellular carcinoma rectum adenocarcinoma
Therapies	mRNA-4106 mRNA-4106 + Nivolumab and relatlimab-rmbw
Age Groups:	senior \| adult
Covered Countries	USA

Facility	City	State	Zip	Country	Details
START Midwest	Grand Rapids	Michigan	49546	United States	Details
START San Antonio	San Antonio	Texas	78229	United States	Details
START Mountain Region	West Valley City	Utah	84119	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06880549Clinical Trial Detail